What Causes Seronegative Rheumatoid Arthritis?

Seronegative rheumatoid arthritis arises from a combination of genetic susceptibility, immune dysregulation, and environmental exposures that differ in important ways from the better-studied seropositive form of the disease. It accounts for roughly 20 to 30 percent of all rheumatoid arthritis cases and is defined by the absence of two blood markers, rheumatoid factor and anti-citrullinated protein antibodies, that doctors rely on to confirm a diagnosis.¹ Researchers increasingly view the two forms not as shades of the same disease but as overlapping yet distinct conditions with different genetic architecture, different pathology inside the joint, and sometimes different responses to medication.²

A Different Genetic Blueprint

The strongest genetic risk factor for seropositive RA is a cluster of immune-system genes called HLA-DRB1, specifically certain variants known as the “shared epitope.” For seronegative disease, the picture looks different. A large-scale genetic mapping study found that the strongest association in seronegative RA was at a different position within the same gene region, amino acid position 11 in HLA-DRβ1, where the presence of certain amino acids carried a modest increase in risk.³ In other words, the two forms of RA share a neighborhood on the genome but park in different spots.

Outside that immune-gene region, researchers have identified susceptibility markers that seem specific to the seronegative form. A replication study confirmed associations with genes called ANKRD55 and BLK, and identified two new loci near the prolactin gene (PRL) and the NFIA gene that were linked to seronegative but not seropositive disease. Neither of those two loci showed up in other common autoimmune conditions, suggesting they mark something genuinely unique about seronegative RA.⁴ The involvement of the prolactin gene is especially intriguing because prolactin is a hormone with known effects on immune-cell behavior, and its connection to seronegative RA has not been fully explored.

Why Smoking Matters Less Than You’d Think

If you have read anything about rheumatoid arthritis risk, you have probably seen smoking listed as a major trigger. That relationship is real, but it applies almost exclusively to seropositive disease, particularly in people who carry shared-epitope genes. For seronegative RA, the story is surprisingly empty. A large Swedish study found that neither smoking nor the shared epitope genes, nor the combination of both, increased the risk of developing the seronegative form.⁵ An earlier study similarly reported that smoking did not predict seronegative RA in men or women.⁶

This is a common misconception worth correcting. People with seronegative RA sometimes blame themselves for smoking history, or doctors may assume smoking contributed to their disease the way it does in seropositive cases. The evidence does not support that assumption. Whatever environmental factors push the immune system toward seronegative RA, cigarette smoke does not appear to be one of them.

The Gut Microbiome and Viral Infections

If smoking isn’t a key environmental trigger for seronegative RA, what is? Researchers have been looking in two directions: the gut and past infections. A Mendelian randomization study, which uses genetic variation to infer cause-and-effect relationships, found that certain gut bacteria were associated with lower risk of seronegative RA, while one group called Ruminococcaceae UCG002 appeared to increase the risk.⁷ The protective and harmful bacteria differed between the seropositive and seronegative forms, adding to the picture of these as distinct conditions sharing a name.

Viral infections also appear relevant. A systematic review of viral exposures and RA risk found that parvovirus B19, hepatitis C, and possibly Epstein-Barr virus were associated with an increased risk of developing RA overall.⁸ Most of these studies did not separate the analysis by serostatus, so it remains unclear whether viral triggers operate differently in people who go on to develop the seronegative versus seropositive form. Chikungunya fever stood out for its association with persistent inflammatory arthritis, and that arthritis is often seronegative. It is plausible that viral infections trigger immune cascading through pathways that do not involve citrullinated proteins, which would explain why the resulting arthritis lacks the characteristic antibodies.

What Looks Different Inside the Joint

Joint tissue from people with seronegative RA is inflamed, but the inflammation has a somewhat different chemical signature. A study comparing the synovial fluid of antibody-positive and antibody-negative patients found that people with seropositive disease had higher levels of several inflammatory molecules, including IL-1β, IL-17F, and a chemokine called CCL-20.⁹ The cellular makeup of the tissue itself, however, was not significantly different between the two groups. So the joints of seronegative patients are populated by the same types of immune cells, but those cells appear to be producing a different mix of inflammatory signals.

This distinction matters because many biologic drugs are designed to block specific inflammatory molecules. If the dominant inflammatory pathways differ, the best drug target may differ too. Ultrasound imaging has confirmed that seronegative RA is not “mild RA” or “not real RA.” A study using high-frequency ultrasound found extensive abnormalities in the joints and tendons of seronegative patients, including bone erosions in over a third of the joints examined. These rates were dramatically higher than what was seen in osteoarthritis controls, where bone erosions showed up in barely one percent of joints.¹⁰

The Diagnostic Problem

Without the two standard blood markers, diagnosing seronegative RA becomes a process of ruling other things out. The challenge is that several other conditions can produce a nearly identical picture: swollen joints, morning stiffness, fatigue, elevated inflammation on blood tests, but no RF or ACPA. Psoriatic arthritis is a frequent look-alike. A metabolomics study attempted to develop a model using blood chemicals and lipid ratios to distinguish seronegative RA from psoriatic arthritis, and it correctly classified about 71 percent of patients in a validation group.¹¹ That is better than a coin flip but far from definitive, which captures the current state of the art.

In older adults, the confusion gets worse. Polymyalgia rheumatica, a condition that causes severe stiffness in the shoulders and hips, can overlap heavily with seronegative RA when it starts in later life. One synthesis of reviews noted that about a quarter of patients with elderly-onset RA initially present with symptoms that look like polymyalgia rheumatica, and roughly 10 percent of those patients eventually develop classic RA features.¹² Shoulder pain, which you might expect to be a distinguishing clue, shows up in both conditions and is therefore unhelpful for telling them apart.

This diagnostic murkiness has real consequences. A delayed or wrong diagnosis means delayed treatment, and in a disease that erodes bone and cartilage, timing matters. It also means some people diagnosed with seronegative RA may actually have a different condition entirely, which muddies the research on what causes seronegative RA and how best to treat it.

New Biomarkers Trying to Fill the Gap

The search for blood tests that can catch seronegative RA has produced several candidates, none yet standard but some promising. Anti-carbamylated protein antibodies (anti-CarP) can show up in people who are negative for the traditional markers. A study evaluating patients referred with suspected RA found isolated anti-CarP positivity in samples that were negative for all three standard tests.¹³ Another candidate is a protein called 14-3-3η (eta), which leaks out of damaged joint cells into the blood. A meta-analysis of studies testing this marker estimated a pooled sensitivity of about 73 percent and specificity of about 88 percent for RA overall.¹⁴ However, blood levels of 14-3-3η tend to be lower in seronegative patients than in seropositive ones, which limits its usefulness precisely in the group that needs the most help getting diagnosed.¹⁵

A more unconventional approach involves looking not at proteins in the blood but at chemical tags on DNA. A study developing a diagnostic test based on DNA methylation patterns in blood reported an overall accuracy of about 89 percent for classifying RA, though accuracy dropped to 75 percent for seronegative disease specifically.¹⁶ Separately, researchers have found that reduced methylation of a gene called HIPK3 shows moderate diagnostic value for RA and can help distinguish seronegative RA from other conditions like ankylosing spondylitis.¹⁷ Small RNA molecules carried in tiny blood vesicles called exosomes are another area of investigation, with early work suggesting that certain exosomal microRNAs could flag subclinical inflammation in seronegative patients before joint damage becomes obvious.¹⁸ None of these are ready for routine clinical use, but they collectively suggest that seronegative RA leaves biological traces — we just haven’t settled on the best way to read them.

How Seronegative RA Behaves Over Time

A common assumption is that seronegative RA runs a milder course. There is some truth to this on average: seronegative disease is associated with milder progression compared to seropositive disease.¹⁹ Extra-articular complications, meaning problems outside the joints like lung fibrosis, rheumatoid nodules, and nerve damage, are more frequent in seropositive patients.²⁰ But “milder on average” is not the same as “mild.” The ultrasound data showing erosions in over a third of seronegative joints makes that clear, and case series have documented severely destructive seronegative RA in individual patients.

One area where seronegative patients may fare worse is osteoporosis. A study comparing extra-articular manifestations found that osteoporosis was more common in the seronegative group, though the difference did not reach statistical significance.²⁰ The reasons for this are not fully understood. It may relate to differences in the inflammatory profile or to the fact that seronegative patients sometimes go longer without diagnosis and treatment, giving bone loss more time to accumulate.

Treatment Response Depends on the Drug

For conventional medications like methotrexate, serostatus does not seem to matter much. A large real-world study found that the one-year treatment effectiveness of disease-modifying drugs was essentially identical between seropositive and seronegative patients, at about 70 percent in each group.²¹ That is reassuring: the bread-and-butter drugs work regardless of what your blood tests show.

Where things diverge is with certain biologic therapies. Rituximab, a drug that depletes B cells (the immune cells that produce antibodies), works better in people who have those antibodies to begin with. A meta-analysis found that seropositive patients had a modestly greater reduction in disease activity on rituximab compared to seronegative patients.²² A trial-level analysis confirmed this pattern: among patients who were RF-positive, rituximab produced significant improvements at 24 weeks, whereas among RF-negative patients, the improvement in one key measure was not statistically significant.²³ A French hospital study similarly found that anti-CCP positivity was a predictor of good response to rituximab.²⁴

This makes biological sense: if the disease is not being driven by antibody-producing B cells, a drug that kills B cells is less likely to hit the right target. For seronegative patients, alternatives that work through different pathways may be more effective. A study tracking drug survival (how long patients stayed on a medication before discontinuing) found that among seronegative patients, tocilizumab, which blocks a different inflammatory molecule, had a significantly higher survival rate than abatacept, a drug that interrupts T-cell activation. TNF-blocking drugs fell in between. In seropositive patients, there was no significant difference among these drug classes.²⁵ These findings suggest that matching the drug to the serostatus could improve outcomes, though current treatment guidelines do not yet make strong distinctions based on antibody status alone.

When a “Seronegative RA” Diagnosis Might Be Wrong

A concern that lurks behind seronegative RA research is that the category itself may be too broad. Some patients labeled seronegative may actually have psoriatic arthritis without obvious skin disease, crystal arthritis that was missed on initial workup, or viral arthritis that persists longer than expected. Others may have a form of spondyloarthritis, which is a family of inflammatory joint diseases often associated with a different genetic marker, HLA-B27, and tends to involve the spine and large joints more than the small joints of the hands and feet.²⁶

This heterogeneity means that studies on “seronegative RA” are likely studying a mix of people with genuinely antibody-negative rheumatoid arthritis and people with other conditions that happen to look similar. As better diagnostic tools come along, some of those people will be reclassified, and the true biology of seronegative RA will come into sharper focus. For people living with the diagnosis today, the practical takeaway is that if treatment is not working well, revisiting whether the diagnosis is correct is not a sign of failure. It is a rational step, given how genuinely difficult the diagnosis is to make.

The Role of Immune Cells Beyond Antibodies

Because seronegative RA lacks the hallmark antibodies, researchers have looked more closely at other branches of the immune system. The innate immune system, the older, less specific arm of immune defense, appears to play a larger role in driving joint inflammation in seronegative disease. Macrophages, neutrophils, and natural killer cells may be more central to the damage than the B cells and plasma cells that dominate in seropositive disease. The different cytokine profiles seen in synovial fluid support this idea: the inflammatory soup in seronegative joints is not just a quieter version of the seropositive soup; its composition is different.⁹

This shift in focus has implications for drug development. Most new RA therapies in the past two decades were designed with seropositive disease in mind, targeting molecules like TNF, B cells, or T-cell co-stimulation that are most active in antibody-driven inflammation. Seronegative patients have been included in the clinical trials for these drugs, but rarely as a pre-specified subgroup with enough statistical power to draw reliable conclusions. The result is that doctors treat seronegative RA with the same drug toolkit and hope it works, adjusting by trial and error when it does not. The emerging understanding of seronegative RA as an immunologically distinct disease makes the case for trials designed around this population specifically, though funding and patient recruitment for such trials remain a challenge.

1
PubMed Central. Seronegative Rheumatoid Arthritis: A Distinct Immunopathological Entity with Erosive Potential
2
PubMed. Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects
3
American Journal of Human Genetics. Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity
4
PubMed Central. Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis
5
PubMed. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis
6
PubMed. Smoking and risk of rheumatoid arthritis
7
PubMed Central. The gut-joint axis: Genetic evidence for a causal association between gut microbiota and seropositive rheumatoid arthritis and seronegative rheumatoid arthritis
8
PubMed. A systematic review of viral exposures as a risk for rheumatoid arthritis
9
PubMed Central. Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients
10
Scientific Reports. High-frequency ultrasound in patients with seronegative rheumatoid arthritis
11
BMJ. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
12
PubMed Central. Differentiating between Seronegative Elderly-Onset Rheumatoid Arthritis and Polymyalgia Rheumatica: A Qualitative Synthesis of Narrative Reviews
13
PubMed Central. Anti-Carbamylated Protein (Anti-CarP) Antibodies in Patients Evaluated for Suspected Rheumatoid Arthritis
14
PubMed Central. The Role of 14-3-3 η as a Biomarker in Rheumatoid Arthritis
15
PubMed Central. Evaluation of 14-3-3eta protein as a diagnostic biomarker in the initial assessment of inflammatory arthritis
16
Arthritis & Rheumatology. Development and Performance of a Diagnostic Precision Biomarker for Seronegative Rheumatoid Arthritis Based on DNA Methylation in Blood
17
PubMed. HIPK3 hypomethylation as a potential epigenetic biomarker in rheumatic immune diseases with emphasis on rheumatoid arthritis
18
Insights-Journal of Life and Social Sciences. CIRCULATING EXOSOMAL MIRNAS AS BIOMARKERS FOR SUBCLINICAL INFLAMMATION IN SERONEGATIVE RHEUMATOID ARTHRITIS
19
PubMed Central. Long-term outcomes of destructive seronegative (rheumatoid) arthritis – description of four clinical cases
20
PubMed Central. Extra-articular manifestations of seronegative and seropositive rheumatoid arthritis
21
PubMed Central. Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
22
Annals of the Rheumatic Diseases. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
23
The Journal of Rheumatology. Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial
24
PubMed. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital
25
PubMed. Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis
26
Clinical Dermatology Review. Skin in Rheumatoid Arthritis and Seronegative Arthritis